Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 378 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR After Chemotherapy, Selma Blair Embraces Her Buzzed “Patchy Charcoal” Hair November 8, 2019 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Adagrasib Following a Re-Examination... November 17, 2023 Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... July 7, 2021 Load more HOT NEWS Can Artificial Intelligence Help See Cancer in New, and Better, Ways? GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... Stressed out – the cancer cells that survive chemotherapy, but at...
